Home > Insider Trading > Filing (0000899243-17-017894)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1420565	Aileron Therapeutics Inc	ALRN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1709654	Scott Kapnick	C/O Aileron Therapeutics, Inc. 281 Albany Street Cambridge MA 02139		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2017-07-05	285,438	$0.00	295,076	No	4	C	Direct
Common Stock	Acquisiton	2017-07-05	159,307	$15.00	454,383	No	4	P	Direct
Common Stock	Acquisiton	2017-07-05	66,666	$15.00	521,049	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Direct
No	4	P	Direct
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series D Preferred Stock	Disposition	2017-07-05	106,856	$0.00	10,753	$0.00
Common Stock	Series D-1 Preferred Stock	Disposition	2017-07-05	363,636	$0.00	36,594	$0.00
Common Stock	Series E-2 Preferred Stock	Disposition	2017-07-05	612,002	$0.00	61,588	$0.00
Common Stock	Series E-3 Preferred Stock	Disposition	2017-07-05	1,266,130	$0.00	127,415	$0.00
Common Stock	Series F Preferred Stock	Disposition	2017-07-05	487,776	$0.00	49,086	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Footnotes

The Series D, Series D-1, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one-basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series D-1, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
These shares are directly owned by Jake86 LLC, for which the Reporting Person serves as investment manager. The Reporting Person disclaims beneficial ownership of the shares held by Jake86 LLC, except to the extent of his indirect pecuniary interest therein.